Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Export 151 results:
Συντάκτης Τίτλος [ Τύπος] Έτος Φίλτρα: Συντάκτης is Mikhailidis, Dimitri P [Clear All Filters]
IMproving the imPlemEntation of cuRrent guidelines for the mAnagement of major coronary hearT disease rIsk factors by multifactorial interVEntion. The IMPERATIVE renal analysis..
Arch Med Sci. 7(6), 984-92.
(2011). Involvement of signaling molecules on na/h exchanger-1 activity in human monocytes..
Open Cardiovasc Med J. 4, 181-8.
(2010). JUPITER: major implications for vascular risk assessment..
Curr Med Res Opin. 25(1), 133-7.
(2009). The JUPITER trial results boost the evidence for the use of hsCRP as a treatment target and as part of the assessment of vascular risk: time for new guidelines?.
Hellenic J Cardiol. 50(2), 89-91.
(2009). Kidney function and estimated vascular risk in patients with primary dyslipidemia..
Open Cardiovasc Med J. 3, 57-68.
(2009). Lipid lowering agents and the endothelium: an update after 4 years..
Curr Vasc Pharmacol. 10(1), 33-41.
(2012). Lipid profile, low-density lipoprotein oxidation and ceruloplasmin in the progeny of families with a positive history of cardiovascular diseases and/or hyperlipidemia..
Angiology. 60(4), 455-61.
(2009). Lipid-lowering agents and new onset diabetes mellitus..
Expert Opin Pharmacother. 11(12), 1965-70.
(2010). Lipids, Statins and Heart Failure: An Update..
Curr Pharm Des. 22(31), 4796-4806.
(2016). Lipoprotein a: where are we now?.
Curr Opin Cardiol. 24(4), 351-7.
(2009). Long-term impact of multifactorial treatment on new-onset diabetes and related cardiovascular events in metabolic syndrome: a post hoc ATTEMPT analysis..
Angiology. 63(5), 358-66.
(2012). Management of statin-intolerant high-risk patients..
Curr Vasc Pharmacol. 8(5), 632-7.
(2010). Managing the combination of non-alcoholic fatty liver disease and metabolic syndrome..
Expert Opin Pharmacother. 13(2), 287-8; author reply 289-90.
(2012). Mechanisms linking nonalcoholic fatty liver disease with coronary artery disease..
Dig Dis Sci. 57(4), 1109.
(2012). Medical treatment as an alternative to adrenalectomy in patients with aldosterone-producing adenomas..
Endocr Relat Cancer. 15(3), 693-700.
(2008). Metabolic syndrome and non-cardiac vascular diseases: an update from human studies..
Curr Pharm Des. 20(31), 4944-52.
(2014). Na+ H+ exchanger-1: a link with atherogenesis?.
Expert Opin Investig Drugs. 19(12), 1545-56.
(2010). Naltrexone sustained-release (SR) + bupropion SR combination therapy for the treatment of obesity: 'a new kid on the block'?.
Ann Med. 43(4), 249-58.
(2011). Non-coronary atherosclerotic cardiovascular disease in patients with familial hypercholesterolaemia..
Curr Med Res Opin. 1-10.
(2020). Novel data on the pathogenesis of atherosclerosis, treatment targets, and new therapeutic interventions in lipid-related cardiovascular risk factors..
Curr Pharm Des. 20(40), 6215-9.
(2014). Obesity, Metabolic Syndrome and the Risk of Microvascular Complications in Patients with Diabetes mellitus..
Curr Pharm Des. 25(18), 2051-2059.
(2019). Omega-3 fatty acids: how can they be used in secondary prevention?.
Curr Atheroscler Rep. 10(6), 510-7.
(2008). Passive smoking: the democratic right of nonsmokers to survive..
Angiology. 62(7), 520-2.
(2011). PCI and stable coronary heart disease--COURAGE to change our minds?.
Curr Vasc Pharmacol. 5(3), 173-4.
(2007). Peripheral artery disease in patients with type 2 diabetes..
J Diabetes Complications. 28(6), 912.
(2014).